COVALON TECHNOLOGIES LTD (COV.CA) Fundamental Analysis & Valuation

TSX-V:COV • CA22282D3022

Current stock price

1.77 CAD
+0.01 (+0.57%)
Last:

This COV.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

6

1. COV.CA Profitability Analysis

1.1 Basic Checks

  • In the past year COV was profitable.
  • In the past year COV had a positive cash flow from operations.
  • In multiple years COV reported negative net income over the last 5 years.
  • In multiple years COV reported negative operating cash flow during the last 5 years.
COV.CA Yearly Net Income VS EBIT VS OCF VS FCFCOV.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M

1.2 Ratios

  • The Return On Assets of COV (5.70%) is better than 95.65% of its industry peers.
  • Looking at the Return On Equity, with a value of 6.70%, COV belongs to the top of the industry, outperforming 95.65% of the companies in the same industry.
  • COV has a better Return On Invested Capital (3.92%) than 95.65% of its industry peers.
Industry RankSector Rank
ROA 5.7%
ROE 6.7%
ROIC 3.92%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
COV.CA Yearly ROA, ROE, ROICCOV.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50

1.3 Margins

  • COV has a better Profit Margin (6.27%) than 95.65% of its industry peers.
  • COV has a Operating Margin of 5.37%. This is amongst the best in the industry. COV outperforms 95.65% of its industry peers.
  • The Gross Margin of COV (53.24%) is better than 86.96% of its industry peers.
  • COV's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 5.37%
PM (TTM) 6.27%
GM 53.24%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.84%
GM growth 5Y9.13%
COV.CA Yearly Profit, Operating, Gross MarginsCOV.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. COV.CA Health Analysis

2.1 Basic Checks

  • COV has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • There is no outstanding debt for COV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
COV.CA Yearly Shares OutstandingCOV.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2024 5M 10M 15M 20M 25M
COV.CA Yearly Total Debt VS Total AssetsCOV.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2024 10M 20M 30M 40M

2.2 Solvency

  • An Altman-Z score of 6.12 indicates that COV is not in any danger for bankruptcy at the moment.
  • COV's Altman-Z score of 6.12 is amongst the best of the industry. COV outperforms 91.30% of its industry peers.
  • The Debt to FCF ratio of COV is 1.56, which is an excellent value as it means it would take COV, only 1.56 years of fcf income to pay off all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 1.56, COV belongs to the top of the industry, outperforming 95.65% of the companies in the same industry.
  • A Debt/Equity ratio of 0.05 indicates that COV is not too dependend on debt financing.
  • COV has a better Debt to Equity ratio (0.05) than 73.91% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 1.56
Altman-Z 6.12
ROIC/WACC0.49
WACC8%
COV.CA Yearly LT Debt VS Equity VS FCFCOV.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M 30M

2.3 Liquidity

  • A Current Ratio of 8.36 indicates that COV has no problem at all paying its short term obligations.
  • The Current ratio of COV (8.36) is better than 95.65% of its industry peers.
  • COV has a Quick Ratio of 6.40. This indicates that COV is financially healthy and has no problem in meeting its short term obligations.
  • COV has a better Quick ratio (6.40) than 95.65% of its industry peers.
Industry RankSector Rank
Current Ratio 8.36
Quick Ratio 6.4
COV.CA Yearly Current Assets VS Current LiabilitesCOV.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2024 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. COV.CA Growth Analysis

3.1 Past

  • The earnings per share for COV have decreased strongly by -82.26% in the last year.
  • The Revenue has been growing slightly by 5.29% in the past year.
  • Measured over the past years, COV shows a quite strong growth in Revenue. The Revenue has been growing by 19.43% on average per year.
EPS 1Y (TTM)-82.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
Revenue 1Y (TTM)5.29%
Revenue growth 3Y21.83%
Revenue growth 5Y19.43%
Sales Q2Q%-15.64%

3.2 Future

  • COV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.60% yearly.
  • The Revenue is expected to grow by 6.78% on average over the next years.
EPS Next Y3%
EPS Next 2Y43.53%
EPS Next 3Y35.75%
EPS Next 5Y27.6%
Revenue Next Year0.99%
Revenue Next 2Y6.81%
Revenue Next 3Y6.78%
Revenue Next 5Y6.78%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
COV.CA Yearly Revenue VS EstimatesCOV.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 10M 20M 30M 40M 50M
COV.CA Yearly EPS VS EstimatesCOV.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 2030 0.05 0.1 0.15 0.2

More info and screens

Find the best growth stocksShow best growing peers

6

4. COV.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 59.00, the valuation of COV can be described as expensive.
  • Based on the Price/Earnings ratio, COV is valued cheaper than 95.65% of the companies in the same industry.
  • COV is valuated expensively when we compare the Price/Earnings ratio to 25.96, which is the current average of the S&P500 Index.
  • The Price/Forward Earnings ratio is 12.27, which indicates a correct valuation of COV.
  • COV's Price/Forward Earnings ratio is rather cheap when compared to the industry. COV is cheaper than 86.96% of the companies in the same industry.
  • COV is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.04, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 59
Fwd PE 12.27
COV.CA Price Earnings VS Forward Price EarningsCOV.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, COV is valued cheaper than 95.65% of the companies in the same industry.
  • 91.30% of the companies in the same industry are more expensive than COV, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 33.9
EV/EBITDA 12.42
COV.CA Per share dataCOV.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0.2 0.4 0.6 0.8 1

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • The decent profitability rating of COV may justify a higher PE ratio.
  • A more expensive valuation may be justified as COV's earnings are expected to grow with 35.75% in the coming years.
PEG (NY)19.67
PEG (5Y)N/A
EPS Next 2Y43.53%
EPS Next 3Y35.75%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. COV.CA Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 8.52%, COV is a good candidate for dividend investing.
  • COV's Dividend Yield is rather good when compared to the industry average which is at 0.47. COV pays more dividend than 100.00% of the companies in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.91, COV pays a better dividend.
Industry RankSector Rank
Dividend Yield 8.52%

5.2 History

  • COV does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
COV.CA Yearly Dividends per shareCOV.CA Yearly Dividends per shareYearly Dividends per share 2025 0.05 0.1

5.3 Sustainability

DPN/A
EPS Next 2Y43.53%
EPS Next 3Y35.75%
COV.CA Yearly Income VS Free CF VS DividendCOV.CA Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M

More info and screens

Find the best dividend stocksShow peers with best dividend

COV.CA Fundamentals: All Metrics, Ratios and Statistics

COVALON TECHNOLOGIES LTD

TSX-V:COV (3/16/2026, 7:00:00 PM)

1.77

+0.01 (+0.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25
Earnings (Next)05-26
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners5.08%
Ins Owner ChangeN/A
Market Cap48.89M
Revenue(TTM)32.82M
Net Income(TTM)2.06M
Analysts84.44
Price Target2.96 (67.23%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 8.52%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)12.14%
Min EPS beat(2)-100%
Max EPS beat(2)124.27%
EPS beat(4)3
Avg EPS beat(4)86.97%
Min EPS beat(4)-100%
Max EPS beat(4)229.45%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-16.25%
Min Revenue beat(2)-19.53%
Max Revenue beat(2)-12.98%
Revenue beat(4)1
Avg Revenue beat(4)-1.09%
Min Revenue beat(4)-19.53%
Max Revenue beat(4)32.12%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-22.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)-41.67%
EPS NY rev (3m)-41.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-5.33%
Revenue NY rev (3m)-8.3%
Valuation
Industry RankSector Rank
PE 59
Fwd PE 12.27
P/S 1.49
P/FCF 33.9
P/OCF 21.36
P/B 1.59
P/tB 1.66
EV/EBITDA 12.42
EPS(TTM)0.03
EY1.69%
EPS(NY)0.14
Fwd EY8.15%
FCF(TTM)0.05
FCFY2.95%
OCF(TTM)0.08
OCFY4.68%
SpS1.19
BVpS1.11
TBVpS1.06
PEG (NY)19.67
PEG (5Y)N/A
Graham Number0.87
Profitability
Industry RankSector Rank
ROA 5.7%
ROE 6.7%
ROCE 5.45%
ROIC 3.92%
ROICexc 8.47%
ROICexgc 9.31%
OM 5.37%
PM (TTM) 6.27%
GM 53.24%
FCFM 4.39%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y8.84%
GM growth 5Y9.13%
F-Score4
Asset Turnover0.91
Health
Industry RankSector Rank
Debt/Equity 0.05
Debt/FCF 1.56
Debt/EBITDA 0.6
Cap/Depr 88.69%
Cap/Sales 2.58%
Interest Coverage 250
Cash Conversion 84.21%
Profit Quality 70.07%
Current Ratio 8.36
Quick Ratio 6.4
Altman-Z 6.12
F-Score4
WACC8%
ROIC/WACC0.49
Cap/Depr(3y)88.92%
Cap/Depr(5y)79.37%
Cap/Sales(3y)2.96%
Cap/Sales(5y)3.15%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-82.26%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-100%
EPS Next Y3%
EPS Next 2Y43.53%
EPS Next 3Y35.75%
EPS Next 5Y27.6%
Revenue 1Y (TTM)5.29%
Revenue growth 3Y21.83%
Revenue growth 5Y19.43%
Sales Q2Q%-15.64%
Revenue Next Year0.99%
Revenue Next 2Y6.81%
Revenue Next 3Y6.78%
Revenue Next 5Y6.78%
EBIT growth 1Y-18.02%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year670.66%
EBIT Next 3Y139.18%
EBIT Next 5Y77.64%
FCF growth 1Y-52.81%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-34.09%
OCF growth 3YN/A
OCF growth 5YN/A

COVALON TECHNOLOGIES LTD / COV.CA Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for COVALON TECHNOLOGIES LTD?

ChartMill assigns a fundamental rating of 6 / 10 to COV.CA.


What is the valuation status for COV stock?

ChartMill assigns a valuation rating of 6 / 10 to COVALON TECHNOLOGIES LTD (COV.CA). This can be considered as Fairly Valued.


Can you provide the profitability details for COVALON TECHNOLOGIES LTD?

COVALON TECHNOLOGIES LTD (COV.CA) has a profitability rating of 6 / 10.


What is the financial health of COVALON TECHNOLOGIES LTD (COV.CA) stock?

The financial health rating of COVALON TECHNOLOGIES LTD (COV.CA) is 8 / 10.